Orgenesis (NASDAQ:ORGS) and BridgeBio Pharma (NASDAQ:BBIO) Head to Head Review

BridgeBio Pharma (NASDAQ:BBIO) and Orgenesis (NASDAQ:ORGS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk and Volatility

BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Valuation and Earnings

This table compares BridgeBio Pharma and Orgenesis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$217.77 million	22.75	-$643.20 million	($2.41)	-10.88
Orgenesis	$662,000.00	10.15	-$55.36 million	N/A	N/A

Orgenesis has lower revenue, but higher earnings than BridgeBio Pharma.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BridgeBio Pharma and Orgenesis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0	2	12	0	2.86
Orgenesis	0	0	0	0	0.00

BridgeBio Pharma currently has a consensus target price of $47.69, indicating a potential upside of 81.96%. Given BridgeBio Pharma’s stronger consensus rating and higher possible upside, research analysts plainly believe BridgeBio Pharma is more favorable than Orgenesis.

Profitability

This table compares BridgeBio Pharma and Orgenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-201.53%	N/A	-74.34%
Orgenesis	-3,827.81%	N/A	-130.18%

Insider and Institutional Ownership

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by insiders. Comparatively, 5.7% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Orgenesis on 9 of the 11 factors compared between the two stocks.

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.